UroGen Pharma Ltd. reported significant financial performance improvements in its latest quarterly filing, with revenues reaching $50.96 million for the three months ended March 31, 2026, compared to $20.25 million during the same period in 2025. This increase of approximately 153% is primarily attributed to the successful launch of Zusduri, which contributed $29.25 million in sales, alongside continued sales of Jelmyto, which generated $21.71 million. The company's gross profit also saw a substantial rise, totaling $46.82 million, up from $17.92 million year-over-year.

Despite the revenue growth, UroGen reported an operating loss of $20.26 million, an improvement from the $36.91 million loss recorded in the prior year. The reduction in operating loss is attributed to a decrease in research and development expenses, which fell to $15.60 million from $19.87 million, as well as an increase in selling, general, and administrative expenses, which rose to $51.49 million from $34.97 million. The net loss for the quarter was $23.57 million, a notable decrease from the $43.84 million loss reported in the same quarter last year.

In terms of operational developments, UroGen has expanded its product offerings with the FDA approval of Zusduri in June 2025, marking it as the first and only FDA-approved treatment for recurrent low-grade intermediate risk non-muscle invasive bladder cancer. The company has also made strategic moves, including a significant refinancing of its debt through a new $250 million loan agreement with Pharmakon Advisors, which is expected to provide additional capital for ongoing operations and product development.

As of March 31, 2026, UroGen's total assets amounted to $253.69 million, up from $200.46 million at the end of 2025, while total liabilities increased to $377.94 million from $305.93 million. The company reported an accumulated deficit of $983.29 million, reflecting its ongoing investment in research and development and commercialization efforts. Looking ahead, UroGen anticipates continued losses as it focuses on the commercialization of its products and further research activities, but management believes it has sufficient cash and cash equivalents to fund operations beyond one year from the issuance of the financial statements.

About UroGen Pharma Ltd.

UroGen Pharma develops innovative, proprietary drug delivery solutions for uro-oncology and urological cancers. Its core technology, RTGel, enables sustained, targeted release of existing and investigational drugs like mitomycin, aiming to improve efficacy and reduce invasiveness of treatments for conditions such as UTUC and bladder cancer. The company focuses on minimally invasive therapies, leveraging its strong IP portfolio and regulatory expertise to address unmet medical needs in the urinary tract.

This description was generated via AI from an annual report. Updated 8 months ago.

About 10-Q Filings

A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.

Key points about the 10-Q:

  • Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
  • Content: It includes:
    • Financial statements showing the company's current financial position
    • Updates from management on the performance and projections of the business
    • Information about potential risks the company faces
    • Details on how the company is run internally
  • Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.